Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TVP-1012 (Azilect) in Japanese Parkinson's Disease Patients with Wearing Off
NCT02337738Phase 3Completed
- Sponsor
- Takeda
- Start
- Jan 2015
- Primary completion
- Sep 2016
- Modality
- Irreversible Covalent Inhibitors
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of rasagiline in Parkinson's disease (PD) (3 arms), sponsored by Takeda. Primary endpoint: Change From Baseline in Mean Daily OFF-time During Treatment Period at 26 weeks. Started Jan 2015; status: completed.
02
Drugs
rasagiline
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT02337738.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02337738.